Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma.
It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors.
In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 25 | -0.11 Increased by 0.00% | -0.10 Decreased by -5.77% |
| Aug 12, 25 | -0.12 Increased by +58.62% | -0.12 |
| May 13, 25 | -0.11 Increased by +52.17% | -0.13 Increased by +15.38% |
| Mar 20, 25 | -0.11 Increased by +45.00% | -0.13 Increased by +15.38% |
| Nov 12, 24 | -0.11 Increased by +45.00% | -0.17 Increased by +35.29% |
| Aug 12, 24 | -0.29 Decreased by -38.10% | -0.18 Decreased by -61.11% |
| May 8, 24 | -0.23 Decreased by -4.55% | -0.20 Decreased by -15.00% |
| Mar 27, 24 | -0.20 Increased by +81.13% | -0.23 Increased by +13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -30.61 M Increased by +1.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -33.88 M Increased by +46.40% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -30.97 M Increased by +11.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 4.20 M Decreased by -24.80% | -32.23 M Decreased by -8.52% | Decreased by -768.16% Decreased by -44.32% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -31.20 M Decreased by -2.76% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -63.20 M Decreased by -98.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -35.02 M Decreased by -5.48% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 5.58 M Increased by +N/A% | -29.70 M Increased by +78.04% | Decreased by -532.28% Decreased by N/A% |